Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden

Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ bu...

Descripción completa

Detalles Bibliográficos
Autores: Marín, Gustavo Horacio, Marín, Lupe, Haag, Griselda Octavia, Risso, Paula, Errecalde, Jorge Oscar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:Argentina
Institución:Universidad Nacional de La Plata
Repositorio:SEDICI (UNLP)
Idioma:inglés
OAI Identifier:oai:sedici.unlp.edu.ar:10915/162137
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/162137
Access Level:acceso abierto
Palabra clave:Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
id AR_4235f150aa4a68e1dddeef4ebdc8ff41
oai_identifier_str oai:sedici.unlp.edu.ar:10915/162137
network_acronym_str AR
network_name_str Argentina
repository_id_str
spelling Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burdenMarín, Gustavo HoracioMarín, LupeHaag, Griselda OctaviaRisso, PaulaErrecalde, Jorge OscarCiencias MédicasBiosimilarsAnaemiaChronicFailureRenalCostBiopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.Facultad de Ciencias MédicasConsejo Nacional de Investigaciones Científicas y TécnicasComisión de Investigaciones Científicas de la provincia de Buenos Aires2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf96-99http://sedici.unlp.edu.ar/handle/10915/162137enginfo:eu-repo/semantics/altIdentifier/issn/1948-593Xinfo:eu-repo/semantics/altIdentifier/doi/10.4172/1948-593X.1000214info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2024-05-08T13:21:25Zoai:sedici.unlp.edu.ar:10915/162137Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292024-05-08 13:21:25.833SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
spellingShingle Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
Marín, Gustavo Horacio
Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
title_short Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_full Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_fullStr Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_full_unstemmed Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
title_sort Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
dc.creator.none.fl_str_mv Marín, Gustavo Horacio
Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
author Marín, Gustavo Horacio
author_facet Marín, Gustavo Horacio
Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
author_role author
author2 Marín, Lupe
Haag, Griselda Octavia
Risso, Paula
Errecalde, Jorge Oscar
author2_role author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
topic Ciencias Médicas
Biosimilars
Anaemia
Chronic
Failure
Renal
Cost
description Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems’ budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/162137
url http://sedici.unlp.edu.ar/handle/10915/162137
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1948-593X
info:eu-repo/semantics/altIdentifier/doi/10.4172/1948-593X.1000214
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
96-99
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1799194557400743936
score 15.811543

Similares en LA Referencia